LRK-4189 escalation

Preclinical

LLARKSPUR BIOSCIENCES, INC.

LRK-4189 escalation is one of 20 therapeutic programs targeting Neoplasms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NeoplasmsRecruiting

NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

29 competitors in Neoplasms

#DrugCompanyPhaseTrials

Alimta

SShawn Eagle

Phase 3

1 2

Fludara

Sanofi

Phase 2

3 3

Cyramza

Eli Lilly

Phase 2

1 4

Gemzar

Johnson & Johnson

Phase 2

1 5

Verzenio

Eli Lilly

Phase 2

1 6

Camptosar

Pfizer

Phase 2

1 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 8

Navelbine

PPierre Fabre Medicament

Phase 2

1 9

Taxotere

AAvyxa

Phase 2

1 10

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Neoplasms

NCT07498725

Clinical

Trials by Indication[1]

Neoplasms1 trial

A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors

Recruiting·LLARKSPUR BIOSCIENCES, INC.·Preclinical·NCT07498725·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LRK-4189 escalation. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for LRK-4189 escalation. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — LARKSPUR BIOSCIENCES, INC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: LLARKSPUR BIOSCIENCES, INC.

LRK-4189 escalation

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Neoplasms1 trial

References

Drug Info

Quick Facts

Related News